Gabapentin
Product Images NDC 68071-2463

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2463). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2463 6)

Gabapentin 600 mg tablets label from NuCare Pharmaceuticals, Inc. The label indicates a count of 60 tablets, each film-coated and scored on both sides. Tablets are white to off-white, debossed with 'SG' on one side and '177' on the other. The label includes the NDC 68071-2463-6 and storage instructions for controlled temperature 68-77°F.*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10. Gabapentin shows a decreasing trend in pain score, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over a 7-week period for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The chart shows a 3-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease in both Gabapentin groups compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' from studies on Gabapentin. It compares percentages of responders in Study 1 and Study 2 between placebo (PBO) and Gabapentin (GBP) at varying dosages (3600 mg, 1800 mg, 2400 mg). The chart includes statistical significance markers for comparisons.*

FDA Label Image

Image-04 (Image 04)

Equation showing the formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients, commonly used in pharmacokinetics and dosing considerations.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing its molecular connectivity with a cyclohexane ring, amino group (CH2NH2), and a carboxylic acid group (CH2CO2H). The diagram depicts the arrangement of these groups in the molecule.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart showing percentage differences on the y-axis and daily dose in milligrams on the x-axis, with data points representing three studies labeled as Study a, Study b, and Study c. Each study is distinguished by different colored squares, plotting differences over various gabapentin daily doses from 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.